S133 Home delivery Pemetrexed post induction therapy in advanced NSCLC

• Research type

  Research Study

• Full title

  Home Delivery of Pemetrexed as Maintenance Treatment in Patients Who Have Not Progressed after Induction Therapy for Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Feasibility Study

• IRAS ID

  81605

• Contact name

  Rohit Lal

• Sponsor organisation

  Eli Lilly and Company

• Eudract number

  2011-000841-19

• ISRCTN Number

  not known

• Research summary

  Pemetrexed is approved as maintenance (long-term) treatment of advanced nonsquamous nonsmall cell lung cancer (NSCLC). The favourable and well characterised safety profile of Pemetrexed and its convenient and short 10 minute administration schedule makes this drug good to give on an outpatient basis. This study aims to evaluate the feasibility of treating patients with Pemetrexed as maintenance treatment in a home setting. To be eligible for enrolment in this study patients must be over 18 years old and have a diagnosis of stage III/IV nonsquamous nonsmall cell lung cancer (NSCLC). It is estimated that each participant will be in the study for a duration of around 15 months and the whole study will last for approximately 27 months.Study assessments will include: Physical examinations, Questionnaires and Blood tests. Radiology scans (CT, MRI or Chest X-Rays may be used).

• REC name

  London - Chelsea Research Ethics Committee

• REC reference

  11/LO/1332

• Date of REC Opinion

  4 Oct 2011

• REC opinion

  Further Information Favourable Opinion